Table 3 Clinical characteristics of the 14 patients who developed PCP without prolonged moderate-to-high corticosteroid dose usage
No | Age (years) | Sex | Cancer type | Coexisting pulmonary diseases | CTx before PCP diagnosis | Days from last CTx to PCP diagnosis | Types/cumulative dosea/total days of corticosteroid administration within 90 days prior to PCP diagnosis | Reason for corticosteroid use | Field/cumulative dose of radiation therapy | Days from last radiation therapy to PCP diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 71 | M | Lung cancer | Lung cancer | Gefitinib Erlotinib CDDP/PEM/Bev Gefitinib | 0 | Daily/630 mg/42 days | Palliative therapy | None | NA |
2 | 90 | M | Renal cancer | IP | None | NA | Daily/960 mg/68 days | Spinal cord compression | Thoracic spine/55 Gy | 61 |
3 | 71 | M | Lung cancer | Lung cancer, COPD, radiation pneumonitis | CDDP/VP-16 | 156 | Daily/560 mg/28 days | Radiation pneumonitis | Lung/39 Gy | 102 |
4 | 64 | M | Esophageal cancer | None | CDDP/5-FU | 58 | Daily/675 mg/38 days Intermittent/223 mg/4 days | Severe drug allergy Antiemetics/premedication for CTx | Esophagus/60 Gy | 54 |
5 | 70 | M | Pancreatic cancer | None | GEM/nabPTX | 13 | Daily/630 mg/42 days Intermittent/248 mg/5 days | Palliative therapy Antiemetics/premedication for CTx | None | NA |
6 | 64 | M | Lung cancer | Lung cancer, radiation pneumonitis | CDDP/S-1 | 107 | Daily/405 mg/20 days | Radiation pneumonitis | Lung/60 Gy | 94 |
7 | 59 | F | Ovarian cancer | None | CBDCA/PTX DOC | 33 | Intermittent/120 mg/2 days | Antiemetics/premedication for CTx | None | NA |
8 | 60 | M | Esophageal cancer | None | 5-FU | 11 | Intermittent/446 mg/8 days | Antiemetics/premedication for CTx | Esophagus/58 Gy | 0 |
9 | 68 | F | Breast cancer | None | ADR/CY | 15 | Intermittent/387 mg/12 days | Antiemetics/premedication for CTx | None | NA |
10 | 67 | M | Lung cancer | Lung cancer | CBDCA/PTX | 98 | None | NA | Lung/66 Gy | 9 |
11 | 67 | M | Laryngeal cancer | Metastatic lung cancer | PTX/Cet | 14 | Intermittent/495 mg/10 days | Antiemetics/premedication for CTx | None | NA |
12 | 72 | M | Lung cancer | Lung cancer | CBDCA/PTX | 64 | Intermittent/248 mg/2 days | Antiemetics/premedication for CTx | Lung/52 Gy | 3 |
13 | 40 | F | Breast cancer | None | CY/EPI/5-FU DOC/HER | 12 | Intermittent/932 mg/14 days | Antiemetics/premedication for CTx | None | NA |
14 | 58 | M | Hypopharyngeal cancer | None | CDDP PTX/Cet | 5 | Intermittent/396 mg/8 days | Antiemetics/premedication for CTx | None | NA |